Blue Jet Healthcare IPO Review, Date, Price, GMP

Blue Jet Healthcare founded in 1968 is a company that specializes in pharmaceutical and healthcare ingredients and intermediates. The company has a business model focused on contract development and manufacturing organization (CDMO) specializing in chemistry capabilities, for media intermediates and high-intensity sweeteners. Their success is attributed to their investments, in research and development (R&D) as well as their robust manufacturing infrastructure.

Blue Jet Healthcare has a range of skills and manufacturing capabilities when it comes to media intermediates and high-intensity sweeteners, like saccharin and its salts. They produce products in their facilities, including important initial materials and advanced intermediate substances. This enables them to have control, over their production process ensuring quality and cost effectiveness.

In the three years Blue Jet Healthcare has issued invoices to, over 350 customers across 35 countries. They have established a customer base by partnering, with both cutting-edge companies and multinational providers of generic pharmaceuticals. This partnership has been strengthened through long-term contracts, which showcase their dedication to providing top-notch services.

Blue Jet Healthcare primarily categorizes its operations into three product categories; (1) contrast media intermediates, (2) high-intensity sweeteners, and (3) pharmaceutical intermediates and active pharmaceutical ingredients (APIs).

1. Contrast Media Intermediates: Blue Jet Healthcare specializes in producing and supplying key intermediates for contrast media used in medical imaging, including X-rays, CT scans, MRI, and ultrasound. The global contrast media market is substantial and expected to grow, with Blue Jet Healthcare maintaining long-term relationships with major manufacturers in the industry.

2. High Intensity Sweeteners: The company engages in the creation, production, and promotion of high-intensity sweeteners with attention, to saccharin and its derivatives. Their approach prioritizes both sustainability and efficient manufacturing. The worldwide market for high-intensity sweeteners encompasses a range of products such, as sucralose, aspartame, saccharin, stevia, and neotame.

3. Pharma Intermediates and APIs: Blue Jet Healthcare functions, as a Contract Development and Manufacturing Organization (CDMO) in the intermediates and active pharmaceutical ingredients (APIs) domain. They work together with both innovator and generic pharmaceutical companies providing intermediates for APIs in therapeutic fields, like cardiovascular health, oncology, and the central nervous system.

Blue Jet Healthcare IPO Complete Details:

Blue Jet Healthcare IPO Timetable:

Company Financial Details:

AS OF NOW, the GMP OF Blue Jet Healthcare is Around 00 Rs.

Objects Of Issue:

The company will not directly benefit from the offer financially as all the proceeds will be received by the selling shareholders. The distribution of these proceeds will be based on the proportion of shares sold by each selling shareholder as part of the offer.

Promoters:

Akshay Bansarilal Arora:

• Age: 59 years
• Position: Executive Chairman of the Company
• Nationality: Indian

Shiven Akshay Arora:

• Age: 28 years
• Position: Managing Director of the Company
• Nationality: Indian

Archana Akshay Arora:

• Age: 52 years
• Position: Head of Business Development of the Company
• Nationality: Indian

FAQs:

Read More:

• Protean eGov Technologies IPO Review, Date, Price, GMP
• Ondoor Concepts IPO Review, Date, Price, GMP
• WomenCart IPO Review, Date, Price, GMP
• Rajgor Castor Derivatives IPO Review, Date, Price, GMP